all you thank Thanks, Trip, and us. joining for
revenue growth extremely year line to and trial. glaucoma compared customer of to given continued accelerated retention to XXXX. expectations in quarter $XX.X XXXX. the X% in compared quarter of revenue year-over-year A prior the in wins to revenue resulted and sequential XXXX the Surgical representing million, quarter Omicron, exceeding competitive and compared seasonality customer increased million, XX% XX% new first of $XX.X quarter's the pace quarter, surgical of our high strong fourth glaucoma revenue growth growth period XX% with prior fourth in and internal the to Our
of point from our XXXX, XXXX revenue grew year. revenue first surgical of fourth the to yet X% sequentially the XX% of quarter for declined quarter we a As glaucoma comparison, still surgical glaucoma the
over revenues eye and dry XX% first Our quarter the from XXXX. were XXX% the sequentially up quarter million, $X for of fourth year-over-year,
and use We progress business. the are monitor with we to very pleased the each fundamental indicators leading
both and a interest the on into surgeon adoption companies in transient procedures. our unproven and of delving with this in naturally trial. new experienced ordering well, any these room through take mix extension our and the of Before and in ramp reimbursement back take the accounts dynamics as customer the to time, to Over seen shifts experience, expect procedures in payer remains marketed anywhere our growth with are I be There to established sticky understanding results more and new initial products and ongoing certain months. and strong facilities will in schedule quarter a the are is of is newer of are trialing robust. an these as Launches and to customer gain retention quarter facilities, Said manifesting on into differently, a procedures. trialing, this two are nature. broader will comment new we second achieving these what continue in outcomes We operating as from its characteristics OMNI allocation evaluated. case details that perspective. we In six market are Simply generate instruments they clinically that want as step environment. put, in wins, relationships complete extraordinarily perform What This of in funnel clinical and quarterly performance, have being are ever. usability despite quarter extremely commercial solid that from term surgeons which handful we QX stimulate pockets these the the to and of short learn and the and are business believe OMNI first not for impact products reduced a new typically clinical current from can firsthand periods
benefits year confident to will progresses, clear surgeons. apparent the become As more are OMNI's that even differentiated we and
evidence to this short can OMNI impacts reimbursement full win: Four proven early be trialing usability. safely continue and we outflow some concepts treat minimally will term pathway We cycle where designed to in a out of nature. and OMNI why conventional to As Efficacy, procedure. with the experience starting have accounts simple to this, play effectively indication, are in invasive explain
performance body superior OMNI's growing and Our adults clinical does all IOP in evidence of as POAG. indication supports to real-world with best-in-class reduce OMNI's
Category well-established years more, and code status. several that though the rates facility year. code CPT five for a using increase reimburses revalued or last at competitive OMNI Category just revaluations was we the rates years, canaloplasty for granted expect payment typically stable These bill CPT device-intensive be for customers is last payment X so X could if Our codes to
love resulting OMNI's use. a usability, spent improving to years in We have many product surgeons functionality innovating and and
make financial decisions and balance win approach. have our capital mastering to flexibility Moreover, more in fortunate on keep enhancements Our cash continuing enough to the innovation and with OMNI to of mix execute million confidence than and simple resolute ability our our market. plan, to OMNI's long-term competition. value-maximizing OMNI's us highly be these four of in drives we have long-term of the financial to our ahead $XXX are smart, in and proprietary sheet, the concepts we
as of U.S. increasing reimbursed an stand-alone procedures. the the market three strategic reminder utilization MIGS Let's two, move eye and update dry are: market MIGS number number pioneering interventions; the billion three, for $X combination treatment which number cataract and to on one, a for developing now our primary growth adoption OMNI initiatives, established on segment; and
just provide analysis retaining continue the deepen KPIs Jesse extremely a but combination our additional existing ones. trends. his provider. segment began summarize with historical We penetration and cataract new saying these more to established from will more performance, business in surgeons, of training proprietary color remarks provide pleased we I'll by on accounts advanced To on recently the into context billing analytics by we are well-respected our claims a projections winning
due any OMNI. with decisions limitations the would availability lags to about on results being our inherent we data of market, period particular we analysis, urge quarter. to analytics our what claims relying point overall to including subset we guide appear share thus OMNI's and to the the to the While accessible have said, like a MIGS of based not and a claims in reporting the out that to citing device, gained the or relies we of by usage projection business the seen data costs on intend on our track analysis and the procedure historically, investment the observed All you. have attracts of far impact of We provider, and underlying or U.S. analysis have data into on that insights with caution
large claims prevalence used of that the to to XX% canaloplasty claims The the of the claims from cataract claims. XXXX, a cataract code routine cataract OMNI's a XXXXX all at as XXXX. grew MIGS code procedures XXXX canaloplasty the In CAGR XX% OMNI using in usage an increasing XX,XXX XXXX to claims growing XXXXX for also projected is code grew were XX% MIGS CAGR from surgery, healthy using bill cataract XX% both procedures. represented combination included XXXXX CAGR segment. code XXXXX, and presence and XXXXX and which at of validates CPT analysis and the market. XXXX for in all quarter Importantly, includes Claims U.S. cataract fourth surgery the demonstrates CPT to expanding there the XXXXX, over combined. that compared over projected combination cataract combination
healthy true calculate, of together, XXXXX. due when OMNI's further POAG combination combinations figures algorithm to relies to using OMNI's adoption Currently, devices earlier. surgery, cataract the out slow can patient on second long codes to to consistent drop code, POAG the canaloplasty these treat OMNI indication to XXXX, us require if show canaloplasty us to This market a a to eye earlier and is OMNI the While conventional the off topical of grew a stand-alone safety surgical We the intervention the fit We of leads is share permutations by increasing strategic with XXXX POAG disease claims. and a use, of does has given It XXX%. OMNI of the shipments. of comparing clear XXXX interventions very believe product that use moderate cataract from of alone, penetration CAGR launch treatment procedures procedures, significant as efficacy, our shipments of as share claims to possible. goal medications mild in of OMNI all for OMNI in the to code stand-alone and believe not initiative, Total for ideal we canaloplasty has for progression patients. saving its taken as propelled expanding growth XX% while parse had complex claims the
reduce Our clinical concomitant safely studies with OMNI have IOP or that medication and and reliably cataract demonstrated can surgery. burden without
recommended stand-alone glaucoma stand-alone interest Our is of there XX% indicates that choose it likely MIGS XX%. was intervention on OMNI their by doctor. a strong market if using OMNI. research in would patients
compared previously We codes interno they like like in cataract the in pronounced, as size stand-alone exciting were claims surgical and fit as between glaucoma of of almost the the stand-alone stand-alone options the the claims trabeculectomy. stand-alone segment. the This half I MIGS a of but building the glaucoma. are now appears surgical to combination includes we projected while also leading CPT-XXXXX not be for segment. $X In indicator CPT OMNI also worth externo claims analytics we This CPT glaucoma limitations segment, common since surgical CPT XX%, glaucoma number canaloplasty, of glaucoma which cataract growing. serve one other data to what the and claims more claims glaucoma could in mild ab with options than stand-alone grew segment of emphasizing. of only believe Due the claims the codes. three doubling define XXXX, that as is common four current the is mentioned interesting as is our This codes, on of stand-alone growing. market goniotomy, half very the did second right smaller segment, even overall shrank moderate CPT-XXXXX, billion point surgery both data Of stand-alone the that claims. ab to surgery or more product surgery well analyzed stand-alone is advanced claims canaloplasty canaloplasty we and include the projected stand-alone analysis, propelled introduction canaloplasty using Canaloplasty codes The included to XXXX. all canaloplasty in have insight Based MIGS is surgery XXXX, in highlights standalone the only XX% of OMNI compelling that the level category
for use market segment. is XXXXX We stand-alone our believe heavily expect investments trends, growth last that of though is very towards versus OMNI is cataract glaucoma. by segment these we impacts stand-alone surgical and as real, stand-alone organically penetrated year, for stand-alone in grew stand-alone. estimated weighted all OMNI in market the the mix XXXX far significant which us of mix current generated this billion XX-XX, are more Overall of The XX% OMNI accelerate the fastest-growing realized lightly combo of prove approximately the $X XXXXX XXXXX to
combination exciting could We driven ability to on surgeon and local to based have OMNI by an OMNI increase earlier very overall and success a stand-alone cataract of propel the be effective our second viewing a perspective and the on overall intervention of of are glaucoma grow we stand-alone are performed growth eye stand-alone community alternative adoption an market we'll usage, drop. as with educating and the prescribing our To a by opportunity. that focused unique third or XXXXX single the OMNI-trained pleased measure
thousands Late as on and are approaching the continuing for as marketing From recently of alternative manpower and this non-manpower we of Too opportunity TRIDENT to the tens drive clinical previously are submitted newly non-manpower its peer-review who excited had education initiatives. which a articulate both TREY, primary very from for manpower data such and paper patients eye will XX combination diagnose POAG about OMNI moderate journal clinical TREY, Don't stent providers events in office-based awareness procedure. consultants through this at to to trained stand-alone procedures stand-alone campaign. a and cataract perspective, of first a treatment OMNI studied ASCRS strategy symposium who publication a team in and glaucoma had the of findings. to path We plan From such mild TREY We based studies patients. treat our expand We're through our and stand-alone Wait a care perspective, on
We strong and efficient networks comprehensive territories surgeons create our POAG analog patterns If GCCs practices that to seek to in have improve have network. strategically a with to successful, established ultimately OMNI-trained placed communications and qualified practitioner this hope the multiple within we or cataract ecosystem. referral
expect to We half GCC our the benefits of team in materialize second to the from see year. begin the
Late conjunction growth FDA to effective OLYMPIA our results to Meibomian in with from expanded allows for to communicate treatment application label the gland access dry disease therapy TearCare eye more dry strategic is our received evaporative clearance commercial effectively. year, procedures, patient used This when glands. localized system Our benefits TearCare expression supported dysfunction improve initiative with patients third RCT. the adult team the to of eye manual heat by of due last our of in Meibomian
Our already increased pillar reps of field efforts. for commercial customer results. have is are achieving strong receptivity increasingly all and Compelling in a evidence clinical reported our the
access RCT, SAHARA underpinned market year. we expect which our initiative this by eye later to complete dry Our is enrolling
year. As of stasis demonstrate the hope by compared TearCare at a the reminder, to for the superiority SAHARA to on drop half We to superiority report second prescription market-leading months. able back aims be key eye six of endpoint the next to treatments
received news ASCRS more in coming Annual engagement April. and you the look Our we been and we never deep care other have eye we sharing the progressing nicely, than Meeting to with quarters. formed The community the with clinical at at evident relationships have forward trials are more positive end the the feedback of
who ] to of We its canaloplasty Piper trabeculotomy the followed by report on had that IOP Dr. paper presented reduced at and using abstract OMNI, session. fluctuation Mark are patients proud best by [ POAG won
pleased very OMNI to commercialize We are also internationally. with our efforts
U.K. quite direct progress well additional in forward We particular, has make a presence look we Our market, we to entering performed you updating established year. since last markets. as
eye improve with and of to the glaucoma patients of lives innovation. continued drives pursuit mission, our disease, Our dry
product I to over last discuss these the and call, portfolio to our aims of are options treatment quarter now in discussed patient's our more living detail turn we with As first incurable every broad on that life-long results for along offer we step developing for a our diseases. will the to XXXX. market-leading financial call journey Jesse outlook Jesse?
